Blood test-guided treatment with AstraZeneca pill cut risk of breast cancer progression, study finds

AstraZeneca's experimental pill camizestrant, guided by blood test detection of early drug resistance, significantly reduced the risk of disease progression or death in breast cancer patients by 56% compared to standard treatments; the trial, involving 3,256 patients with advanced hormone receptor-positive, HER2-negative breast cancer, showed a statistically significant 16-month progression-free survival for camizestrant versus 9.2 months for standard therapy, potentially establishing a new treatment paradigm pending FDA approval. Separately, AstraZeneca's durvalumab immunotherapy combined with chemotherapy extended event-free survival by 29% in early-stage stomach and esophageal cancer patients, indicating immunotherapy's effectiveness in early-stage disease.

Analysis

AstraZeneca's experimental breast cancer pill, camizestrant, demonstrated a significant clinical benefit in a late-stage trial, reducing the risk of disease progression or death by 56% for patients with advanced hormone receptor-positive, HER2-negative breast cancer exhibiting early signs of resistance to standard therapies. The study, presented at the American Society of Clinical Oncology (ASCO) meeting and published in the New England Journal of Medicine, utilized a novel approach involving liquid biopsies to detect ESR1 mutations, prompting an early switch to camizestrant plus a CDK4/6 inhibitor. This strategy resulted in a median progression-free survival of 16.0 months, compared to 9.2 months for patients continuing standard treatment, a statistically significant improvement with no new safety concerns reported. While camizestrant awaits FDA approval, these findings suggest a potential paradigm shift in treating this common form of breast cancer, moving towards proactive intervention based on molecular markers, especially as approximately 40% of patients on standard aromatase inhibitors develop such resistance mutations. Separately, AstraZeneca also reported positive Phase III results for its immunotherapy durvalumab (Imfinzi) in early-stage stomach and esophageal cancers; when combined with FLOT chemotherapy, durvalumab improved event-free survival by 29% compared to chemotherapy alone, indicating its expanding utility in earlier disease settings and potentially changing practice for these patients.

Key Decisions for Investors

• The compelling Phase III results for camizestrant, demonstrating a 56% reduction in disease progression or death and a novel liquid biopsy-guided approach, significantly bolster its prospects in the substantial breast cancer market, contingent on FDA approval, and underscore AstraZeneca's innovative capabilities.
• Investors should closely monitor the regulatory submission and review process for camizestrant, as its potential approval could serve as a significant catalyst for AstraZeneca, altering treatment landscapes and driving future revenue.
• The positive data for durvalumab in early-stage gastroesophageal cancers further solidify the growth outlook for AstraZeneca's oncology franchise, highlighting the company's success in expanding its key immunotherapy into earlier lines of treatment.